Fig. 2.
Fig. 2. In vitro migration of Cb2-EGFP–expressing cells following 2-AG stimulation. / (A) Cb2-EGFP–expressing 32D/G-CSF-R cells (clones 1-8) and EGFP control 32D/G-CSF-R cells (clones 9-12) were exposed to 300 nM 2-AG (+) or nothing (−) in a transwell assay. The y-axis shows percentage of migration from an input of 2 × 105 cells. (B) Effect of the Cb1-specific antagonist SR141716 (C1) or Cb2-specific antagonist SR155528 (C2) on 2-AG–induced migration of 3 Cb2-EGFP–expressing clones (nos. 2, 5, and 7) and 2 EGFP control clones (nos. 10 and 12). The y-axis shows percentage of migration from an input of 2 × 105 cells.

In vitro migration of Cb2-EGFP–expressing cells following 2-AG stimulation.

(A) Cb2-EGFP–expressing 32D/G-CSF-R cells (clones 1-8) and EGFP control 32D/G-CSF-R cells (clones 9-12) were exposed to 300 nM 2-AG (+) or nothing (−) in a transwell assay. The y-axis shows percentage of migration from an input of 2 × 105 cells. (B) Effect of the Cb1-specific antagonist SR141716 (C1) or Cb2-specific antagonist SR155528 (C2) on 2-AG–induced migration of 3 Cb2-EGFP–expressing clones (nos. 2, 5, and 7) and 2 EGFP control clones (nos. 10 and 12). The y-axis shows percentage of migration from an input of 2 × 105 cells.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal